Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol study evaluating trametinib for cancers with NF1 genetic changes has posted results; the trial is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic and Lymphoid Cell Neoplasm
• Lymphoma
• Malignant Solid Neoplasm
• Multiple Myeloma

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-08-02